The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Interim results from PX-171-006, a phase (Ph) II multicenter dose-expansion study of carfilzomib (CFZ), lenalidomide (LEN), and low-dose dexamethasone (loDex) in relapsed and/or refractory multiple myeloma (R/R MM).
M. Wang
Research Funding - Celgene; Millennium; Novartis; Onyx
W. Bensinger
Consultant or Advisory Role - Onyx
Honoraria - Celgene
Research Funding - Onyx
T. Martin
Consultant or Advisory Role - Onyx
Honoraria - Celgene
M. Alsina
Consultant or Advisory Role - Millennium; Novartis
Honoraria - Celgene; Millennium
D. S. D. Siegel
Honoraria - Celgene; Millennium
N. Y. Gabrail
No relevant relationships to disclose
P. Hari
No relevant relationships to disclose
S. Singhal
Consultant or Advisory Role - Celgene; Takeda
Research Funding - Onyx
R. A. Vescio
No relevant relationships to disclose
S. E. Assouline
No relevant relationships to disclose
L. A. Kunkel
Stock Ownership - Onyx; Onyx
M. Vallone
Employment or Leadership Position - Onyx
Stock Ownership - Onyx
A. Wong
Employment or Leadership Position - Onyx
Stock Ownership - Onyx
R. Niesvizky
No relevant relationships to disclose